VolitionRx Limited (NYSE American: VNRX) has filed a strategic patent application for the use of its proprietary Nu.Q technology in triaging and monitoring patients suspected of Ebola virus infection, the company announced. The application builds on Volition’s existing Nu.Q NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality.
The company’s CE-Marked automated Nu.Q NETs assay and a recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. Volition is seeking partnerships with global health organizations, pharmaceutical developers, NGOs, and distribution partners to support field trials, manufacturing scale-up, and potential deployment in outbreak zones.
This development is significant because Ebola outbreaks often overwhelm fragile health systems in sub-Saharan Africa. Rapid and affordable diagnostic tools are critical for early identification of infected individuals, which can help contain the spread of the virus and allocate limited medical resources effectively. The Nu.Q NETs test, which detects markers of hyper-inflammation, may also help distinguish Ebola from other febrile illnesses common in endemic areas.
Volition’s technology leverages the science of epigenetics to develop simple, cost-effective blood tests for detecting and monitoring a range of diseases, including certain cancers and sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The patent application underscores Volition’s commitment to expanding its intellectual property portfolio in infectious diseases. By targeting Ebola, the company addresses a pressing global health need: the World Health Organization has identified Ebola as a priority pathogen requiring urgent research and development efforts.
Volition’s finger-prick prototype is particularly noteworthy because it could enable testing in remote settings without laboratory infrastructure. If successful, the test could be deployed during outbreaks to quickly triage patients, reduce transmission, and improve survival rates through early supportive care.
The company is actively pursuing collaborations to advance the technology. Partnerships with organizations experienced in outbreak response, such as the WHO or Médecins Sans Frontières, could accelerate field validation and regulatory approvals. Volition’s move into Ebola diagnostics also highlights the broader potential of its Nu.Q platform for other infectious diseases.
For more information, visit the company’s website at https://volition.com/.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VolitionRx Files Patent for Ebola Triage Test Using Nu.Q Technology.